focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

25 Sep 2017 07:01

RNS Number : 6347R
Motif Bio PLC
25 September 2017
 



 

 

 

25 September 2017

 

Motif Bio plc

("Motif" or the "Group")

 

Holding(s) in the Company

 

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 22 September 2017 by Amphion Innovations plc ("Amphion") that a total of 4,390,000 ordinary shares in the Company had been sold in respect of a partial repayment of a loan facility, which is secured by Motif Bio shares held by Amphion. Amphion is now the beneficial owner of 37,150,645 ordinary shares in the Company, representing 14.1% of the issued share capital.

 

Following this sale, Amphion has agreed an amendment to the loan facility with its lender such that no further Motif Bio shares will be sold before 15 January 2018. The full details of this amendment may be found in the RNS announcement released by Amphion today.

 

The TR-1 disclosure is set out below.

 

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Motif Bio plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Amphion Innovations plc

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

September 22 2017

6. Date on which issuer notified (DD/MM/YYYY):

September 22 2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

14.1%

263,128,775

Position of previous notification (if

applicable)

15.8%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB008BVVT4H71

37,150,645

14.1%

SUBTOTAL 8. A

37,150,645

14.1%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Date of completion

September 22 2017

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFLIALIVFID
Date   Source Headline
19th Mar 20204:43 pmRNSSecond Price Monitoring Extn
19th Mar 20204:39 pmRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSCorporate Update
12th Mar 20204:42 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 202012:02 pmRNSPrice Monitoring Extension
7th Feb 20204:35 pmRNSPrice Monitoring Extension
28th Jan 20204:40 pmRNSSecond Price Monitoring Extn
28th Jan 20204:35 pmRNSPrice Monitoring Extension
28th Jan 20207:00 amRNSCorporate Update
22nd Jan 20204:40 pmRNSSecond Price Monitoring Extn
22nd Jan 20204:35 pmRNSPrice Monitoring Extension
17th Jan 202012:12 pmRNSHolding(s) in Company
16th Jan 20204:41 pmRNSSecond Price Monitoring Extn
16th Jan 20204:35 pmRNSPrice Monitoring Extension
16th Jan 202012:07 pmRNSSecond Price Monitoring Extn
16th Jan 202012:02 pmRNSPrice Monitoring Extension
14th Jan 202012:35 pmRNSHolding(s) in Company
10th Jan 20209:55 amRNSHolding(s) in Company
6th Jan 20204:40 pmRNSSecond Price Monitoring Extn
6th Jan 20204:35 pmRNSPrice Monitoring Extension
3rd Jan 202010:42 amRNSHolding(s) in Company
23rd Dec 20199:45 amRNSHolding(s) in Company
19th Dec 20194:29 pmRNSHolding(s) in Company
19th Dec 20194:25 pmRNSHolding(s) in Company
10th Dec 20197:00 amRNSVoluntary delisting from the NASDAQ Capital Market
6th Dec 201911:14 amRNSHolding(s) in Company
29th Nov 201912:20 pmRNSHolding(s) in Company
29th Nov 20197:00 amRNSTotal Voting Rights
27th Nov 20197:00 amRNSADS Program and Warrant Agent Agreement
26th Nov 20197:00 amRNSVoluntary Delisting from the Nasdaq Capital Market
20th Nov 20195:51 pmRNSHolding(s) in Company
18th Nov 201912:12 pmRNSDirectorate Changes
14th Nov 20196:13 pmRNSResult of General Meeting
11th Nov 20197:00 amRNSSettlement Agreement
28th Oct 20194:14 pmRNSHolding(s) in Company
25th Oct 20193:51 pmRNSHolding(s) in Company
25th Oct 201912:07 pmRNSSecond Price Monitoring Extn
25th Oct 201912:02 pmRNSPrice Monitoring Extension
25th Oct 20197:00 amRNSPosting of Circular and Notice of General Meeting
24th Oct 20197:00 amRNSU.S. Army-funded project to Evaluate Iclaprim
21st Oct 20193:00 pmRNSTiming of General Meeting and Circular
21st Oct 201912:07 pmRNSSecond Price Monitoring Extn
21st Oct 201912:02 pmRNSPrice Monitoring Extension
10th Oct 20197:00 amRNSMotif Bio confirms receipt of FDA meeting minutes
3rd Oct 201912:07 pmRNSSecond Price Monitoring Extn
3rd Oct 201912:02 pmRNSPrice Monitoring Extension
3rd Oct 20197:00 amRNSChange of Adviser
2nd Oct 20197:00 amRNSConditional Placing
30th Sep 20194:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.